shigella conjugate vaccines
Vaccineexperimental
Clinical trial activity
6 trials · 10 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
4
Phase 3
1
Phase 4
0
Earliest trial started Jan 1, 2003 (NCT00368316)
Timeline
Indications
Mechanism of action
- ShigellaImmunity, active
Shigella immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- shigella conjugate vaccines
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07205926 | Phase 1 | Oct 9, 2025 | Inventprise Inc. |
| NCT06523231 | Phase 2 | Nov 30, 2024 | Kenya Medical Research Institute, LimmaTech Biologics AG |
| NCT06615375 | Phase 2 | Oct 31, 2024 | Emory University, Johns Hopkins University, LimmaTech Biologics AG, University of Cincinnati |
| NCT04056117 | Phase 1/Phase 2 (Phase 2) | Aug 31, 2019 | Kenya Medical Research Institute, LimmaTech Biologics AG, Wellcome Trust |
| NCT01069471 | Phase 1 | Feb 1, 2010 | GlycoVaxyn |
| NCT00368316 | Phase 3 | Jan 1, 2003 | National Institutes of Health (NIH), Tel Aviv University |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (10)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| LimmaTech Biologics AG | For profit | 3 | 3 | 1 | 2019 |
| Kenya Medical Research Institute | Academic/Hospital | 2 | 0 | 1 | 2019 |
| Emory University | Academic/Hospital | 1 | 0 | 1 | 2024 |
| GlycoVaxyn | For profit | 1 | 1 | 1 | 2010 |
| Inventprise Inc. | For profit | 1 | 1 | 1 | 2025 |
| Johns Hopkins University | Academic/Hospital | 1 | 0 | 1 | 2024 |
| National Institutes of Health (NIH) | Government | 1 | 1 | 1 | 2003 |
| Tel Aviv University | Academic/Hospital | 1 | 0 | 1 | 2003 |
| University of Cincinnati | Academic/Hospital | 1 | 0 | 1 | 2024 |
| Wellcome Trust | Academic/Hospital | 1 | 0 | 1 | 2019 |
10 organizations
Page 1 / 1